Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Non-squamous Non-small Cell Lung Cancer

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Relapsed Pediatric Solid Tumor

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Diffuse Intrinsic Pontine Glioma

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Metastatic Pancreatic Adenocarcinoma

Drug-Related Side Effects and Adverse Reactions

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Gastrointestinal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Advanced Stage Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

EGFR Mutation Positive Non-small Cell Lung Cancer

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

ROME

BEVERLY

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Efficacy and Safety of Precision Therapy in Refractory Tumor

BELLA

ANSWER

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

EMERGING

BIOMEDE

BRILLIANT

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

ML22774

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

TREND

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

GITIC

RT Plus EGFR-TKI for Wild-type NSCLC

TCL-1

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

CURCUMIN

NSCLC EGFR TKI

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

TRACTS

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Oncology

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

ROLE

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

TAILOR

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

The Continuation of Erlotinib

RT0901

ERLOPET

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer